<DOC>
	<DOC>NCT02370251</DOC>
	<brief_summary>This is a single-assignment study to evaluate whether Omegaven (IV fish oil) is effective at treating liver disease in children on long-term IV nutrition.</brief_summary>
	<brief_title>Compassionate Use of Omegaven in Children</brief_title>
	<detailed_description>Children up to 18 years of age, on parenteral nutrition, with a direct bilirubin level of 2 mg/dL or greater will be eligible to receive Omegaven at a maximum dose of 1 g/kg/day. Up to 200 children will be eligible for enrollment. Direct bilirubin levels and other labs will be monitored as well as growth parameters.</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Gastroschisis</mesh_term>
	<mesh_term>Infant, Premature, Diseases</mesh_term>
	<mesh_term>Intestinal Atresia</mesh_term>
	<mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Live in or temporarily relocate to Oklahoma Age less than 18 years, both sexes, all races Have a direct bilirubin level of â‰¥2 mg/dL for two consecutive weeks after at least 14 days of parenteral nutrition Received parenteral lipids at a maximum dose of 1.5 g/kg/day (21 g/kg over the two weeks prior) Are not currently enrolled in another lipid emulsion study Known food allergy to fish Known metabolic disorder of lipid metabolism Active coagulopathies (active bleeding or requiring blood product treatment in the prior 48 hours) Medical condition likely to result in death in the next 30 days</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fat Emulsions, Intravenous</keyword>
	<keyword>Parenteral-Nutrition-Associated Liver Disease</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Omegaven</keyword>
	<keyword>Fish Oil</keyword>
</DOC>